Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2a via AKT in prostate cancer cells

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6289-6299

  Vignarajan, Soma ^a   Xie, Chanlu ^a,e   Yao, Mu ^a   Sun, Yuting ^b   Simanainen, Ulla ^c   Sved, Paul ^a   Liu, Tao ^b,d   Dong, Qihan ^a,e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

AKT; Cytosolic phospholipase A2; Prostate cancer; PTEN

Indexed keywords

CYTOSOLIC PHOSPHOLIPASE A2; CYTOSOLIC PHOSPHOLIPASE A2ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; PHOSPHOLIPASE A2; PTEN PROTEIN, HUMAN; PTEN PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; ANIMAL; DEFICIENCY; GENETIC TRANSFECTION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE; MICE, KNOCKOUT; PHOSPHOLIPASES A2; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84906234126     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2198     Document Type: Article

References (44)

1. Engelman JA, Luo J, Cantley LC, Engelman JA, Luo J and Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics. 2006; 7(8):606-619.
2. Manning BD, Cantley LC, Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-1274.
3. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ and Waterfield MD. Synthesis and function of 3-phosphorylated inositol lipids. Annual Review of Biochemistry. 2001; 70:535-602.
4. Chalhoub N and Baker SJ. PTEN and the PI3K pathway in cancer. Annu Rev Pathol Mech Dis 2009; 4:127-150.
5. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI, Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R and Kreisberg JI. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clinical Cancer Research. 2002; 8(4):1168-1171.
6. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. American Journal of Pathology. 2001; 159(2):431-437.
7. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM, Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Research. 2004; 64(15):5232-5236.
8. McCall P, Witton CJ, Grimsley S, Nielsen KV and Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? British Journal of Cancer. 2008; 99(8):1296-1301.
9. Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S and Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer. 2012; 12:543.
10. McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N, Lih FB, O'Rourke D, Whelan J, McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, et al. Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. American Journal of Pathology. 2008; 173(1):229-241.
11. Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K, Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KGD and McHugh K. Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia (New York). 2006; 8(2):112-124.
12. Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D'Agostino R, Zhang H, Wu H, Kang JX, Chen YQ, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. Journal of Clinical Investigation. 2007; 117(7):1866-1875.
13. Ghosh J and Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochemical & Biophysical Research Communications. 1997; 235(2):418-423.
14. Patel MI, Kurek C, Dong Q, Patel MI, Kurek C and Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. Journal of Urology. 2008; 179(5):1668-1675.
15. Chaudry AA, Wahle KW, McClinton S and Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. International Journal of Cancer. 1994; 57(2):176-180.
16. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C and Wallen E. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clinical Cancer Research. 2006; 12((7 Pt 1)):2172-2177.
17. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ and Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. [see comment]. Journal of Clinical Oncology. 2006; 24(18):2723-2728.
18. Leslie CC. Regulation of arachidonic acid availability for eicosanoid production. Biochemistry & Cell Biology. 2004; 82(1):1-17.
19. Ghosh M, Tucker DE, Burchett SA and Leslie CC. Properties of the Group IV phospholipase A2 family. Progress in Lipid Research. 2006; 45(6):487-510.
20. Hua S, Yao M, Vignarajan S, Witting P, Hejazi L, Gong Z, Teng Y, Niknami M, Assinder S, Richardson D and Dong Q. Cytosolic phospholipase A2 sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells. Biochimica et Biophysica Acta. 2013; 1831(6):1146-1157.
21. Dong. (2009). Phospholipase A2. In: Schwab M, ed. Cancer Encyclopedia: Spinger UK).
22. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ and Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Letters. 2006; 240(1):9-16.
23. Patel MI, Singh J, Niknami M, Kurek C, Yao M, Lu S, Maclean F, King NJ, Gelb MH, Scott KF, Russell PJ, Boulas J and Dong Q. Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clinical Cancer Research. 2008; 14(24):8070-8079.
24. Hughes-Fulford M, Tjandrawinata RR, Li C-F and Sayyah S. Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis. 2005; 26(9):1520-1526.
25. Pineiro R, Maffucci T and Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene. 2011; 30(2):142- 152.
26. Ross S, Essary B, de la Houssaye BA, Pan Z, Mikule K, Mubarak O and Pfenninger KH. Thrombin causes pseudopod detachment via a pathway involving cytosolic phospholipase A2 and 12/15-lipoxygenase products. Cell Growth & Differentiation. 2000; 11(1):19-30.
27. Assinder SJ, Dong Q, Kovacevic Z and Richardson DR. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J. 2009; 417(2):411-421.
28. Assinder SJ, Dong Q, Mangs H and Richardson DR. Pharmacological targeting of the integrated protein kinase B, phosphatase and tensin homolog deleted on chromosome 10, and transforming growth factor-beta pathways in prostate cancer. Mol Pharmacol. 2009; 75(3):429-436.
29. Li J, Yen C, Liaw D, Padsypanina K, Bose S, Wang S, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner S, Giovanella B, Ittmann M, tycko B, Hibshoosh H, Wigler M, et al. PTEN a putative tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275:1943-1947.
30. Tucker DE, Ghosh M, Ghomashchi F, Loper R, Suram S, John BS, Girotti M, Bollinger JG, Gelb MH, Leslie CC, Tucker DE, Ghosh M, Ghomashchi F, Loper R, Suram S, John BS, et al. Role of phosphorylation and basic residues in the catalytic domain of cytosolic phospholipase A2alpha in regulating interfacial kinetics and binding and cellular function. Journal of Biological Chemistry. 2009; 284(14):9596-9611.
31. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 1998; 58(13):2720-2723.
32. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A and Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993; 72(2):269-278.
33. Leslie CC. Properties and regulation of cytosolic phospholipase A2. [Review] [77 refs]. Journal of Biological Chemistry. 1997; 272(27):16709-16712.
34. Gordon RD, Leighton IA, Campbell DG, Cohen P, Creaney A, Wilton DC, Masters DJ, Ritchie GA, Mott R, Taylor IW, Bundell KR, Douglas L, Morten J and Needham M. Cloning and expression of cystolic phospholipase A2 (cPLA2) and a naturally occurring variant. Phosphorylation of Ser505 of recombinant cPLA2 by p42 mitogen-activated protein kinase results in an increase in specific activity. Eur J Biochem. 1996; 238(3):690-697.
35. Bandyopadhyay S, Pai SK, Watabe M, Gross SC, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Markwell SJ, Wang Y, Huggenvik J, Pauza ME, Iiizumi M and Watabe K. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene. 2005; 24(34):5389-5395.
36. Swinnen JV, Heemers H, Deboel L, Foufelle F, Heyns W and Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene. 2000; 19(45):5173-5181.
37. van den Bergh RC, Essink-Bot ML, Roobol MJ, Wolters T, Schroder FH, Bangma CH, Steyerberg EW, van den Bergh RCN, Essink-Bot M-L, Roobol MJ, Wolters T, Schroder FH, Bangma CH and Steyerberg EW. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009; 115(17):3868-3878.
38. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH and Schroder FH. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. European Urology. 2009; 55(1):1-8.
39. Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, Yoshimura Y, Suzuki M, Shuto K and Koda K. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol. 2013; 43(2):431-438.
40. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A and Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene. 2005; 24(22):3574-3582.
41. Jin CL, McKeehan K and Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate. 2003; 57(2):160-164.
42. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X and Wu H. Cre/LoxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002; 32(2):148-149.
43. Pileri SA, Roncador G, Ceccarelli C, Piccioli M, Briskomatis A, Sabattini E, Ascani S, Santini D, Piccaluga PP, Leone O, Damiani S, Ercolessi C, Sandri F, Pieri F, Leoncini L and Falini B. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. Journal of Pathology. 1997; 183(1):116-123.
44. Sun Y, Liu PY, Scarlett CJ, Malyukova A, Liu B, Marshall GM, MacKenzie KL, Biankin AV and Liu T. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. Oncogene. 2014; 33(23):2987-2994.